Vifor and Luitpold present anaemia drug data included in US resubmission
This article was originally published in Scrip
Executive Summary
Vifor Pharma (part of the Galenica Group) and its US partner, Luitpold Pharmaceuticals, have revealed the trial data that formed part of a re-submission to the US FDA for Injectafer (ferric carboxymaltose, known as Ferinject in the US), for the treatment of patients with iron deficiency anaemia.